Analyzing genetic changes in patients with acute myeloid leukemia during treatment
Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments
This study is trying to see how genetic changes in acute myeloid leukemia patients with FLT3 mutations affect their response to treatment, to help identify those who might not respond well.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Trial ID | NCT06764459 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with acute myeloid leukemia (AML) who have mutations in the FLT3 gene. It employs single-cell molecular characterization techniques to identify and track the evolution of cancer cell clones and subclones throughout treatment. By understanding how these genetic profiles change under therapeutic pressure, the study aims to uncover mechanisms of resistance to FLT3 inhibitors. Ultimately, the goal is to develop new molecular markers that can help identify patients who are likely to be resistant to treatment early on, thereby improving their therapeutic management.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with FLT3 mutated acute myeloid leukemia.
Not a fit: Patients who respond well to therapy and do not have FLT3 mutations may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with FLT3 mutated AML.
How similar studies have performed: Other studies have shown promise in using molecular characterization to understand treatment resistance in leukemia, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * FLT3 mutated Exclusion Criteria: * Respoder to therapy
Where this trial is running
Bologna
- IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola — Bologna, Italy (Recruiting)
Study contacts
- Principal investigator: Emanuela Ottaviani, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Emanuela Ottaviani, MD
- Email: emanuela.ottaviani@aosp.bo.it
- Phone: 0039 0512144055
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.